Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JNJ-64179375 vs Apixaban in TKR
NCT03251482Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Nov 2017
- Primary completion
- Nov 2018
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 16
01
Overview
Phase 2, randomised, double-blind trial of ichorcumab in venous thromboembolism (VTE) (11 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Number of Participants With Treatment-emergent Bleeding Events and Number of Participants With Total Venous Thromboembolism (VTE). Started Nov 2017; status: completed.
02
Drugs
ichorcumab
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on NCT03251482.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03251482.